In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GENESIS Pharma S.A.

https://www.genesispharma.com

Latest From GENESIS Pharma S.A.

Henlius Sees Revenues Soar In 2022, Q1 2023, As New Plant Bears Fruit

Chinese player Shanghai Henlius Biotech has published unaudited financial results for the first three months of 2023, in the wake of its 2022 annual report.

Sales & Earnings Strategy

Strides And Orbicular Agree Alliance To Develop Nasal Sprays

Strides has agreed to partner with Orbicular to develop four nasal sprays targeting a combined market worth more than $400m for markets including Europe and the US.

Deals Generic Drugs

Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out

The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.

Approvals Business Strategies

Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat

Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.

China Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register